Article

Daily Medication Pearl: Dapagliflozin (Farxiga) for Type 2 Diabetes Mellitus

By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose.

Medication Pearl of the Day: Dapagliflozin (Farxiga)

Indication: Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Insight:

  • Dosing: The recommended starting dose is 5 mg once daily, taken in the morning, with or without food.
  • Dosage form: Tablets 5 mg and 10 mg.
  • Adverse events (AEs): The most common AEs associated with dapagliflozin(5% or greater incidence) were female genital mycotic infections, nasopharyngitis, and urinary tract infections.
  • Mechanism of action: Dapagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose, lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
  • Manufacturer: AstraZeneca

Sources:

label (fda.gov)

farxiga image - Google Search

Related Videos
Woman experiencing pain related to recurrent pericarditis -- Image credit: Art_Photo | stock.adobe.com
Pharmacist assisting a patient with pericarditis -- Image credit: Yuri Arcurs/peopleimages.com | stock.adobe.com
Patient receiving diabetes consultation -- Image credit: Syda Productions | stock.adobe.com
California Wildfires, Pharmacies, Community | image Credit: J Bettencourt/peopleimages.com | stock.adobe.com
California Wildfire, Pharmacy, Community | Image Credit: Erin | stock.adobe.com
Allergies, Asthma, Biologic Treatment, Pharmacists | Image Credit: Pixel-Shot | stock.adobe.com